-
公开(公告)号：US20180362482A1
公开(公告)日：2018-12-20
申请号：US16061597
申请日：2016-12-12
Applicant: Merck Sharp & Dohme Corp.
Inventor： Yongxin Han , Abdelghani Achab , Purakkattle Biju , Yongqi Deng , Xavier Fradera , Liangqin Guo , Shuwen He , Joseph Kozlowski , Ravi Kurukulasuriya , Kun Liu , Meredeth Ann McGowan , Qinglin Pu , Nunzio Sciammetta , Hongjun Zhang , Hua Zhou
IPC: C07D271/08 , C07D285/10 , C07D413/12 , A61P25/24 , A61P25/28 , A61P35/02 , A61P31/14 , A61P27/12 , A61P37/06
CPC classification number: C07D271/08 , A61P25/24 , A61P25/28 , A61P27/12 , A61P31/14 , A61P35/02 , A61P37/06 , C07D285/10 , C07D413/12 , C07D417/12 , C07F9/65318
Abstract: Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.
-
公开(公告)号：US20180016239A1
公开(公告)日：2018-01-18
申请号：US15549465
申请日：2016-02-11
Applicant: Merck Sharp & Dohme Corp.
Inventor： Blair T. Lapointe , Peter H. Fuller , Hakan Gunaydin , Kun Liu , Nunzio Sciammetta , Benjamin Wesley Trotter , Hongjun Zhang , Kenneth J. Barr , John K. F. Maclean , Danielle F. Molinari , Vladimir Simov
IPC: C07D231/56 , A61K31/416 , A61K45/06 , C07D487/04
CPC classification number: C07D231/56 , A61K31/416 , A61K45/06 , A61K2300/00 , C07D403/12 , C07D405/12 , C07D413/06 , C07D471/04 , C07D487/04 , C07D487/06 , C07D487/14 , C07D491/052 , C07D491/107 , C07D495/04 , C07D513/04 , Y02A50/409
Abstract: The present invention relates to compounds according to Formula (I-1) and pharmaceutically acceptable salts thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.
-
公开(公告)号：US20170247377A1
公开(公告)日：2017-08-31
申请号：US15512081
申请日：2015-09-14
Applicant: Kun LIU , Shuwen HE , Jared N. CUMMING , Andrew W. STAMFORD , Merck Sharp & Dohme Corp.
Inventor： Kun Liu , Shuwen He , Jared N. Cumming , Andrew W. Stamford
IPC: C07D471/04
CPC classification number: C07D471/04 , A61K45/06 , A61P25/00
Abstract: In its many embodiments, the present invention provides certain C-6 spirocarbocyclic iminothiadiazine compounds, including compounds Formula (I) or a tautomer thereof, and pharmaceutically acceptable salts of said compounds and said tautomers, wherein R1A, R1B, R2, RA, ring A, RA, m, L1, RL, ring C, RC, and p are as defined herein. The novel compounds of the invention are useful as BACE inhibitors and/or for the treatment and prevention of various pathologies related thereto. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use, including for the possible treatment of Alzheimer's disease, are also disclosed.
-
公开(公告)号：US20170008906A1
公开(公告)日：2017-01-12
申请号：US15272669
申请日：2016-09-22
Applicant: Merck Sharp & Dohme Corp.
Inventor： Craig A. Coburn , Steven W. Ludmerer , Kun Liu , Hao Wu , Richard Soll , Bin Zhong , Jian Zhu
IPC: C07D498/04 , A61K31/4178 , A61K31/553 , A61K45/06 , A61K31/5365
CPC classification number: C07D498/04 , A61K31/4025 , A61K31/404 , A61K31/4178 , A61K31/4184 , A61K31/423 , A61K31/437 , A61K31/4439 , A61K31/4985 , A61K31/506 , A61K31/5365 , A61K31/5377 , A61K31/5383 , A61K31/553 , A61K38/05 , A61K38/06 , A61K45/06 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D409/14 , C07D413/14 , C07D471/04 , C07D487/04 , C07D498/10 , C07K5/06 , C07K5/08
Abstract: The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5A inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5A activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.
Abstract translation: 本发明涉及可用作丙型肝炎病毒（HCV）NS5A抑制剂，这种化合物的合成以及这些化合物用于抑制HCV NS5A活性用于治疗或预防HCV感染的用途的式（I）化合物和 抑制基于细胞的系统中的HCV病毒复制和/或病毒生产。
-
公开(公告)号：US20140371138A1
公开(公告)日：2014-12-18
申请号：US14473117
申请日：2014-08-29
Applicant: Merck Sharp & Dohme Corp.
Inventor： Craig A. Coburn , John A. McCauley , Steven W. Ludmerer , Kun Liu , Joseph P. Vacca , Hao Wu , Bin Hu , Richard Soll , Fei Sun , Xinghai Wang , Man Yan , Chengren Zhang , Mingwei Zheng , Bin Zhong , Jian Zhu
IPC: C07K5/08 , A61K38/05 , A61K38/06 , C07D471/04 , A61K31/437 , C07K5/06 , A61K45/06
CPC classification number: C07D498/04 , A61K31/4025 , A61K31/404 , A61K31/4178 , A61K31/4184 , A61K31/423 , A61K31/437 , A61K31/4439 , A61K31/4985 , A61K31/506 , A61K31/5365 , A61K31/5377 , A61K31/5383 , A61K31/553 , A61K38/05 , A61K38/06 , A61K45/06 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D409/14 , C07D413/14 , C07D471/04 , C07D487/04 , C07D498/10 , C07K5/06 , C07K5/08
Abstract: The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5A inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5A activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.
Abstract translation: 本发明涉及可用作丙型肝炎病毒（HCV）NS5A抑制剂，这种化合物的合成以及这些化合物用于抑制HCV NS5A活性用于治疗或预防HCV感染的用途的式（I）化合物和 抑制基于细胞的系统中的HCV病毒复制和/或病毒生产。
-
Patent Agency Ranking
公开(公告)号：US20220356182A1
公开(公告)日：2022-11-10
申请号：US17324799
申请日：2021-05-19
Applicant: Merck Sharp & Dohme Corp.
Inventor： Craig A. Coburn , Steven W. Ludmerer , Kun Liu , Hao Wu , Richard Soll , Bin Zhong , Jian Zhu
IPC: C07D471/04 , C07D407/14 , A61K31/4985 , A61K31/4439 , A61K31/4184 , A61K31/423 , A61K31/4025 , A61K31/519 , A61K31/404 , A61K31/506 , A61K31/5377 , A61K31/427 , A61K31/4245 , A61K31/475 , A61K31/536 , A61K31/4178 , A61K31/517 , A61K31/5386 , A61K31/553 , C07D487/04 , C07D401/14 , C07D403/14 , C07D403/12 , C07D413/14 , C07D405/14 , C07D405/12 , C07D417/14 , C07D409/14 , A61K31/437
Abstract: The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5A inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5A activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.
-
27.发明申请公开(公告)号：US20200277252A1
公开(公告)日：2020-09-03
申请号：US16753035
申请日：2018-10-04
Applicant: Meredeth Ann McGowan , Abdelghani Achab , Xavier Fradera , Yongxin Han , Derun Li , Jongwon Lim , Kun Liu , Nunzio Sciammetta , Catherine M. White , Wensheng Yu , Hongjun Zhang , Hua Zhou , MERCK SHARP & DOHME CORP.
Inventor： Meredeth Ann McGowan , Abdelghani Achab , Xavier Fradera , Yongxin Han , Derun Li , Jongwon Lim , Kun Liu , Nunzio Sciammetta , Catherine M. White , Wensheng Yu , Hongjun Zhang , Hua Zhou
IPC: C07C237/42 , C07D241/24 , C07D213/82 , C07D233/90 , C07D263/34 , C07D231/14 , C07D277/56 , C07D239/28 , C07D213/75 , C07D309/14 , C07D237/20 , C07D307/14 , C07D205/04 , C07D285/06 , C07D487/04
Abstract: Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: (Formula (I)). Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of a composition in the potential treatment or prevention of an IDO-associated disease or disorder.
-
28.发明申请公开(公告)号：US20200095212A1
公开(公告)日：2020-03-26
申请号：US16483957
申请日：2018-02-19
Applicant: Merck Sharp & Dohme Corp.
Inventor： Kun Liu , Dane Clausen , Liangqin Guo , Yongxin Han , Shuwen He , Joseph Kozlowski , Derun Li , Qinglin Pu , Wensheng Yu , Hongjun Zhang
IPC: C07D271/08 , C07D413/12
Abstract: Compounds of Formula I, or a pharmaceutically acceptable salt, solvate or hydrate thereof: (I). Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.
-
公开(公告)号：US20190276438A1
公开(公告)日：2019-09-12
申请号：US16356172
申请日：2019-03-18
Applicant: Merck Sharp & Dohme Corp.
Inventor： Blair T. Lapointe , Peter H. Fuller , Hakan Gunaydin , Kun Liu , Mark E. Scott , B. Wesley Trotter , Hongjun Zhang
IPC: C07D403/08 , A61P19/02 , C07D401/12 , C07D401/06 , C07D491/107 , C07D491/048 , C07D403/12 , C07D487/04 , C07D405/12 , C07D403/14 , C07D403/06 , C07D231/56 , C07D487/10
Abstract: The present invention relates to compounds according to Formula I and pharmaceutically acceptable salts thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.
-
公开(公告)号：US20180312489A1
公开(公告)日：2018-11-01
申请号：US15770256
申请日：2016-10-27
Applicant: Merck Sharp & Dohme Corp.
Inventor： Blair T. Lapointe , Peter H. Fuller , Hakan Gunaydin , Kun Liu , Mark E. Scott , B. Wesley Trotter , Hongjun Zhang
IPC: C07D403/08 , C07D487/10 , C07D403/14 , C07D491/107 , C07D487/04 , C07D405/12 , C07D401/12 , C07D231/56 , A61P19/02
CPC classification number: C07D403/08 , A61P19/02 , C07D231/56 , C07D401/06 , C07D401/12 , C07D403/06 , C07D403/12 , C07D403/14 , C07D405/12 , C07D487/04 , C07D487/10 , C07D491/048 , C07D491/107
Abstract: The present invention relates to compounds according to Formula (I) and pharmaceutically acceptable salts thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.
-
-
-
-
-
-
-
-
-
Search Results
58
records
(took 0.035 seconds)
